Managing Tenders in the Procurement of Advanced Medical Devices: An Original Model Based on the Net Monetary Benefit Combined With Three Clinical Endpoints

In medical devices, recent studies have proposed original approaches for standardizing competitive tenders with the aim of promoting reproducibility, avoiding discretional decisions, and applying value-based principles. In the framework of tenders' standardization, the net monetary benefit (NMB) method has attracted much interest, but its mathematical complexity has prevented a wide application. In the present work, we developed a procurement model that simplifies clinical information management for high-technology devices purchased for our public hospitals. Our objective was to promote the application of NMB in competitive tenders, particularly at the final stage of the procurement process, where the tender scores are determined. Software to facilitate this task in everyday practice has been developed. This software is made available through the present technical report. We surveyed the most relevant literature about NMB to select the main models commonly used in the studies published thus far. Standard equations of cost-effectiveness were identified. A simplified computation model based on three clinical endpoints was developed to estimate the NMB with less mathematical complexity. This model is proposed as an alternative to the standard approach based on a full economic analysis. The model developed herein has been implemented in a web-based software freely available on the Internet. This software is accompanied by a detailed description of the equations by which the NMB is estimated. A detailed application example is reported; a real tender carried out in 2021 has been re-examined for this purpose. In this re-analysis, the new software has been used to calculate the NMB of three devices. To our knowledge, this is the first experience in which an institution of the Italian healthcare system has evaluated the NMB as a tool for determining tender scores. The model is designed to offer performance similar to a full economic analysis. Our preliminary results are encouraging and suggest a wider application of this method. This approach has important implications regarding cost-effectiveness and cost containment because a value-based procurement is known to maximize effectiveness without determining an increase in costs.

[1]  G. Borselli,et al.  Relationship Between Price and Diagnosis-Related Group Tariff for Medical Devices Assessed by a Regional Health Technology Assessment Committee , 2022, Cureus.

[2]  A. Messori,et al.  Defining innovativeness of high-technology medical devices in an Italian region , 2022, European journal of hospital pharmacy : science and practice.

[3]  S. Karimi,et al.  Value-Based procurement for medical devices: A scoping review , 2021, Medical journal of the Islamic Republic of Iran.

[4]  L. Prieto-Pinto,et al.  International Experience in Therapeutic Value and Value-Based Pricing: A Rapid Review of the Literature. , 2020, Value in health regional issues.

[5]  T. Shiroiwa Cost-effectiveness evaluation for pricing medicines and devices: A new value-based price adjustment system in Japan , 2020, International Journal of Technology Assessment in Health Care.

[6]  C. Jommi,et al.  Implementation of Value-based Pricing for Medicines. , 2019, Clinical therapeutics.

[7]  Andrea Messori,et al.  Tenders for the Procurement of Medical Devices: Adapting Cost-Effectiveness Rules to the Requirements of the European Public Procurement Directive , 2019, Therapeutic Innovation & Regulatory Science.

[8]  A. Messori,et al.  Tenders for the Procurement of Medical Devices: Adapting Cost-Effectiveness Rules to the Requirements of the European Public Procurement Directive , 2019, Therapeutic innovation & regulatory science.

[9]  P. Bach,et al.  Value-Based Pricing for Drugs: Theme and Variations. , 2018, JAMA.

[10]  A. Messori,et al.  Value-based procurement of medical devices: Application to devices for mechanical thrombectomy in ischemic stroke , 2018, Clinical Neurology and Neurosurgery.

[11]  A. Messori,et al.  Value-based procurement of prostheses for total knee replacement , 2017, Orthopedic reviews.

[12]  A. Messori,et al.  Handling the procurement of prostheses for total hip replacement: description of an original value based approach and application to a real-life dataset reported in the UK , 2017, BMJ Open.

[13]  A. Messori,et al.  The results of a pharmacoeconomic study: incremental cost-effectiveness ratio versus net monetary benefit , 2017, Heart.

[14]  Sabrina Trippoli,et al.  Incremental cost-effectiveness ratio and net monetary benefit: Current use in pharmacoeconomics and future perspectives. , 2017, European journal of internal medicine.

[15]  Dan Greenberg,et al.  Bias in published cost effectiveness studies: systematic review , 2006, BMJ : British Medical Journal.

[16]  P. Corr,et al.  Page Proof Instructions and Queries , 2018 .

[17]  M. Neyt Value-Based Pricing: Do Not Throw Away the Baby with the Bath Water , 2017, PharmacoEconomics.